Outlook Therapeutics, Inc.
Current Promotions
No video available
Get in Touch
About
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.
Keywords
No keywords available
Amenities
No amenities listed yet
Upcoming Events
No upcoming events scheduled
Frequently Asked Questions
No FAQs available for this business.
Reviews
No reviews yet. Be the first to review!
Social Links
Photo Gallery
No photos available
Contact Information
Business Info
Location
Business Hours
Business hours not available
Own This Business?
Unclaimed
Take control of your business page to update information, respond to reviews, and more.
Claim This Business